News Posts List
Halyard Health, Inc. announced it has entered into a definitive agreement to acquire CoolSystems, Inc., marketed as Game Ready, a market-leading provider of cold therapy and compression therapy systems for a total consideration of $65 million in cash. Game Ready develops, manufactures and markets the Game Ready® product line, used in the pain management and rehabilitation of patients recovering from orthopedic surgery or sports-related injuries. Its product line includes GRPro 2.1 cold and compression therapy system; Med4 Elite™ multi-modality therapy unit; ATX Wraps; and a variety of product accessories, all of which complement Halyard's existing Pain Management portfolio. Game Ready's innovative brands have helped build a strong reputation within the medical community. The Company's customer base includes some of the world's leading orthopedic hospitals and athletic organizations, providing Halyard greater access to the orthopedic and sports medicine markets. GRPro, the flagship Game Ready product, includes a portable control unit and portfolio of anatomical wraps and sleeves, which deliver controlled cold and compression therapy to all major body parts. Game Ready's new rehabilitation product, Med4Elite, performs rapid contrast therapy with compression.
National Bioscience Industry Report Shows $2T Economic Impact, Accelerated Venture Capital Investment & Job Growth
A study released today at the BIO International Convention shows that the U.S. bioscience industry has reached $2 trillion in annual economic impact while maintaining accelerated venture capital investment and job growth numbers. Among U.S. technology sectors, the bioscience industry has held a leading position as an economic driver and job generator. The report, Investment, Innovation and Job Creation in a Growing U.S. Bioscience Industry 2018, finds U.S. bioscience firms directly employ 1.74 million people, a figure that includes more than 273,000 high-paying jobs created since 2001. The average annual wage for a U.S. bioscience worker reached $98,961 in 2016. These earnings are more than $45,000 greater, on average, than the overall U.S. private sector wage. The report further shows that since 2014, the bioscience industry has grown by 4.4 percent with four of its five major subsectors contributing to this overall job gain. For the first time, the biennial report includes a full assessment of the economic impact of the bioscience industry and finds its total economic impact on the U.S. economy, as measured by overall output, totaled $2 trillion in 2016. This impact is generated by the direct output of the bioscience industry combined with the indirect (supply chain) and induced (employee spending) impacts. The industry and its associated economic output support 8 million jobs throughout the entire U.S. economy through both indirect and induced effects.
The Coalition of State Bioscience Institutes (CSBI) Releases the 2018 Life Sciences Workforce Trends Report at BIO
“Key Findings Support Industry as a Leading US Employer, providing 1.73 Million Jobs” The Coalition of State Bioscience Institutes (CSBI) released the 2018 Life Sciences Workforce Trends Report today at the BIO International Conventionheld this week in Boston, Massachusetts. The report provides a national snapshot of the current and anticipated talent needs of the nation’s dynamic life science industry. The industry continues to be a leading driver of employment across the country, providing 1.73 million jobs in 85,000 companies. In 2017, employers listed almost 264,000 postings for life science positions. Building on the success of its three prior reports, the 2018 CSBI Workforce Trends Report identifies the most pressing talent needs of the life science industry and the key trends that are driving talent acquisition. With the breakneck speed of new discoveries in the industry and shifting global and regulatory environments, there is growing demand for people with new technical and “soft” skills that can navigate this complex wave of change.
ALPHARETTA, Ga., June 1, 2018 /PRNewswire/ -- Halyard Health, Inc. (NYSE: HYH) a market-leading medical devices company, today announced the business' rebrand to Avanos Medical, Inc. ("Avanos"). Avanos' vision is to be the best at getting patients back to the things that matter. Derived from the words "advanced" and "innovation," the new name and brand emphasize the company's focus on innovating with speed to deliver better, more sustainable patient outcomes. Avanos provides pioneering pain management and chronic care therapies and solutions, with a relentless focus on advancing change in the medical devices industry to address unmet medical needs and improve patients' quality of life.
Dune Medical Devices has appointed Alan Bond as Chief Financial Officer. Bond is a veteran financial executive with an extensive record of developing and implementing strategy, and driving revenue and profitability in the medical device industry. Bond joins the Dune Atlanta office after years with McKesson and Given Imaging. “Alan has experience in both large and small organizations during times where the companies were undergoing significant strategic changes and acquisitions,” says Lori Chmura, CEO of Dune Medical. “His experience in driving organizational performance will add significantly to Dune Medical’s capability to manage new growth, and we are pleased to add him to our distinguished team.”
Nutriband Inc. (OTC: NTRB), a Nevada Corporation, is pleased to announce the acquisition of 4P Therapeutics Inc. on April 5, 2018. Nutriband has acquired 100% interest in 4P Therapeutics for a total of $1,900,000 payable in both company stock and cash. 4P Therapeutics will receive 250,000 shares of common stock and a cash amount of $400,000. Steven Damon, CEO of 4P Therapeutics, has been appointed to the Nutriband Inc. Board of Directors. 4P Therapeutics will now become the Pharmaceutical and Development arm of Nutriband Inc. with a specific focus on Transdermal and Topical Technologies, prescription drugs and clinical development. Included in the acquisition of 4P's IP Portfolio is Defent™ abuse deterrent patch technology, an opioid abuse deterrent platform for the transdermal delivery of opioid-based medications. Defent™ lowers the risk of abuse and misuse, creating a safer treatment for patients.
A new group of proteins called cytokines, critical for antimicrobial activity and repairing the damaged intestinal tissue found in inflammatory bowel disease (IBD), has been discovered by researchers in a study led by Georgia State University. The research team examined acute intestinal disease in the colons of mice and found a specific network of proinflammatory cytokines was activated in response to intestinal barrier damage and instrumental in repairing the damaged tissue. Cytokines are small proteins that are produced in response to microbial threat and aid in the recruitment and activation of immune cells to protect the host. The findings, which have potential implications for the treatment of intestinal inflammatory conditions, are published in the journal Proceedings of the National Academy of Sciences.
A method to activate targeted drugs, or smart drugs, only at the selected site of action, an approach that improves the drug’s therapeutic effect and minimizes side effects, has been developed in a study led by Georgia State University. Smart drugs, developed to improve the delivery problems of pharmaceutical drugs, are like guided missiles with warheads. They need a targeting molecule to guide pharmaceutical drug molecules to the desired site of action and a trigger to “drop the bomb” or release or activate the drug. In chemistry terms, such smart drugs are conjugates, or links, between a targeting molecule and a drug molecule. For the most part, the issue of guiding and enriching such smart drugs to the desired site of action has been resolved. An example is the use of antibody-drug conjugates, an emerging class of cancer treatment that targets the delivery of drugs to cancer cells. However, the issue of when and how to trigger drug release, particularly at a sufficiently high concentration, has been a challenging task.
UCB announces BRIVIACT® (brivaracetam) now approved by FDA to treat partial-onset (focal) seizures in pediatric epilepsy patients
UCB announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for the company’s newest anti-epileptic drug (AED) BRIVIACT® (brivaracetam) CV oral formulations indicated as monotherapy and adjunctive therapy in the treatment of partial onset (focal) seizures in patients age four years and older. This approval provides clinicians with the convenient option to prescribe BRIVIACT to their pediatric patients as a tablet or oral solution, providing flexible administration options which are important considerations when treating children. As the safety of BRIVIACT injection has not been established in pediatric patients, BRIVIACT injection is indicated for the treatment of partial-onset seizures only in patients 16 years of age and older. Please see additional BRIVIACT Important Safety Information below.
BIO President and CEO Jim Greenwood issued the following statement after President Trump announced his administration’s plan to lower prescription drug costs: “The men and women of the biopharmaceutical industry work every day to help cure disease and improve the lives of patients. Our country leads the world in the discovery of new treatments because of gifted researchers, dedicated entrepreneurs and a competitive marketplace that recognizes the inherent risks of biomedical innovation. But developing cures and treatments is not enough. These advances in medicine must also be accessible and affordable for patients.
|Neon CRM by Neon One|